Pharmacologic Control of CAR T Cells
نویسندگان
چکیده
منابع مشابه
Design and development of CAR-T cells for cancer therapy
Introduction: Today, treatment with CAR-T cells is accepted as an effective treatment for blood malignancies. CAR-T cells are autologous T cells that are engineered by gene transfer techniques to express a chimeric antigen receptor (CAR). Despite the promising results and the approval of six CAR-T cell products; these products have not yet been approved for solid tumors. In addition, the high c...
متن کاملEngineering CAR-T cells: Design concepts.
Despite being empirically designed based on a simple understanding of TCR signaling, T cells engineered with chimeric antigen receptors (CARs) have been remarkably successful in treating patients with advanced refractory B cell malignancies. However, many challenges remain in improving the safety and efficacy of this therapy and extending it toward the treatment of epithelial cancers. Other asp...
متن کاملVersatile CAR T-cells for cancer immunotherapy
Chimeric antigen receptor (CAR) T-cell therapy has been clinically proven to efficiently combat haematological malignancies. However, continuous efforts are required to increase the specificity of CAR T-cells against tumour versus normal tissues, and are essential to improve their antitumour activity in solid tumours. This review summarises the structure of major CAR designs, and strategies to ...
متن کاملCAR T- cellها: درمانی هدف‌مند در سرطان
سابقه و هدف: با توسعه و پیشرفت روزافزون در زمینة ایمنی‌درمانی تومورها، امروزه توجه خاصی به درمان‌های ایمنی انواع سرطان‌ها معطوف شده است. درمان‌های بر پایة گیرنده‌های کایمری آنتی‌ژن‌ها (CARs)، یکی از انواع درمان‌های مبتنی بر سلول‌های Tی تغییریافته به‌شمار می‌رود که به‌صورت هدف‌مند تنها روی سلول‌های توموری فرد و نه سلول‌های طبیعی اثر می‌گذارد. مواد و روش‌ها: پژوهش‌ها در دهه‌های اخیر حاکی از این ا...
متن کاملSingle cell metrics of the efficacy of CAR T cells
T cells genetically modified to enforce expression of a chimeric antigen receptor (CAR) have shown considerable promise in clinical trials even in tumors refractory to all other treatment methods. In particular, the use of CAR T cells rendered specific for CD19 demonstrated significant anti-tumor effects in patients with CD19 chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Molecular Sciences
سال: 2021
ISSN: 1422-0067
DOI: 10.3390/ijms22094320